Source: Eur Respir J, 50 (2) 1701360; 10.1183/13993003.01360-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Arnaud A. Mailleux, Bruno Crestani. Licence to kill senescent cells in idiopathic pulmonary fibrosis?. Eur Respir J, 50 (2) 1701360; 10.1183/13993003.01360-2017

Member's Comments

No comment yet.

Related content which might interest you: Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Tryptase+ mast cells associate with fibrotic regions in the lungs of idiopathic pulmonary fibrosis patients; a multiplex staining approach Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease Year: 2016 Apoptosis in epithelial cells in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 481s Year: 2004 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (2) 1802441; 10.1183/13993003.02441-2018 Year: 2019 Human airway trypsin-like protease: Friend or foe in idiopathic pulmonary fibrosis? Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Modulation of lung CD11c+ dendritic cells by TGF-β in pulmonary fibrosis in mice Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Immunologically 'supercharged' monocytes as drivers of chronic fibrosis in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us? Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Anti-parietal cell autoimmunity in IPF patients Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Fibrocytes are a potential source of fibroblasts in idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 719s Year: 2007 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 LSC - 2020 - Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis patients Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020